Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 410579, 9 pages
http://dx.doi.org/10.1155/2012/410579
Research Article

Correlation between Blood Activin Levels and Clinical Parameters of Type 2 Diabetes

1Monash Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia
2School of Public Health, Monash University, Clayton, VIC 3168, Australia
3Prince Henry's Institute, Melbourne, VIC 3168, Australia
4Paranta Biosciences, Richmond, VIC 3121, Australia

Received 26 September 2012; Accepted 15 November 2012

Academic Editor: Daisuke Koya

Copyright © 2012 Hui Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 3015–3025, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Sjoholm and T. Nystrom, “Inflammation and the etiology of type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 1, pp. 4–10, 2006. View at Publisher · View at Google Scholar
  3. J. N. Fain, “Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells,” Vitamins and Hormones, vol. 74, pp. 443–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. O. T. Hardy, R. A. Perugini, S. M. Nicoloro et al., “Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity,” Surgery for Obesity and Related Diseases, vol. 7, no. 1, pp. 60–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Plomgaard, K. Bouzakri, R. Krogh-Madsen, B. Mittendorfer, J. R. Zierath, and B. K. Pedersen, “Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation,” Diabetes, vol. 54, no. 10, pp. 2939–2945, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. T. Wunderlich, T. Luedde, S. Singer et al., “Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1297–1302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Kewalramani, P. J. Bilan, and A. Klip, “Muscle insulin resistance: assault by lipids, cytokines and local macrophages,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 13, no. 4, pp. 382–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Navarro-Gonzalez, C. Mora-Fernandez, M. Gomez-Chinchon et al., “Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 1, pp. 51–59, 2010. View at Google Scholar
  9. G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman, “Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance,” The Journal of Clinical Investigation, vol. 95, no. 5, pp. 2409–2415, 1995. View at Google Scholar · View at Scopus
  10. X. Sun, F. Han, J. Yi, L. Han, and B. Wang, “Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats,” Journal of Korean Medical Science, vol. 26, no. 6, pp. 765–770, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gupta-Ganguli, K. Cox, B. Means, I. Gerling, and S. S. Solomon, “Does therapy with anti-TNF-α improve glucose tolerance and control in patients with type 2 diabetes?” Diabetes Care, vol. 34, no. 7, pp. e121–e121, 2011. View at Publisher · View at Google Scholar
  12. D. J. Phillips, D. M. de Kretser, and M. P. Hedger, “Activin and related proteins in inflammation: not just interested bystanders,” Cytokine and Growth Factor Reviews, vol. 20, no. 2, pp. 153–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Jones, A. Mansell, S. Patella et al., “Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16239–16244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Hashimoto and M. Funaba, “Activin in glucose metabolism,” Vitamins and Hormones, vol. 85, pp. 217–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Watanabe, “Activin receptor-like kinase and the insulin gene,” Vitamins and Hormones, vol. 85, pp. 1–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Q. Zhang, M. M. Cleary, Y. Si et al., “Inhibition of activin signaling induces pancreatic epithelial cell expansion and diminishes terminal differentiation of pancreatic β-cells,” Diabetes, vol. 53, no. 8, pp. 2024–2033, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Ogawa, M. Funaba, Y. Chen, and M. Tsujimoto, “Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages,” The Journal of Immunology, vol. 177, no. 10, pp. 6787–6794, 2006. View at Google Scholar · View at Scopus
  18. M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, “Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects,” Diabetes Care, vol. 33, no. 4, pp. 861–868, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Chen, H. F. Chen, S. U. Chen, H. N. Ho, Y. S. Yang, and W. S. Yang, “The relationship between follistatin and chronic low-grade inflammation in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 92, no. 6, pp. 2041–2044, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Google Scholar
  21. P. G. Knight, S. Muttukrishna, and N. P. Groome, “Development and application of a two-site enzyme immunoassay for the determination of ‘total’ activin-A concentrations in serum and follicular fluid,” Journal of Endocrinology, vol. 148, no. 2, pp. 267–279, 1996. View at Google Scholar · View at Scopus
  22. H. Ludlow, D. J. Phillips, M. Myers et al., “A new ‘total’ activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples,” Clinical Endocrinology, vol. 71, no. 6, pp. 867–873, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. E. O'Connor, J. R. McFarlane, S. Hayward, T. Yohkaichiya, N. P. Groome, and D. M. De Kretser, “Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study,” Human Reproduction, vol. 14, no. 3, pp. 827–832, 1999. View at Google Scholar · View at Scopus
  24. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  25. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar · View at Scopus
  26. S. T. Chari, M. Zapiach, D. Yadav, and R. A. Rizza, “Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance,” Pancreatology, vol. 5, no. 2-3, pp. 229–233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Tura, A. Mari, C. Winzer, A. Kautzky-Willer, and G. Pacini, “Impaired β-cell function in lean normotolerant former gestational diabetic women,” European Journal of Clinical Investigation, vol. 36, no. 1, pp. 22–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation, WHO Document Production Services, Geneva, Switzerland, 2006.
  29. “Standards of medical care in diabetes—2010,” Diabetes Care, vol. 33, supplement 1, pp. S11–S61, 2010. View at Publisher · View at Google Scholar
  30. G. Ø. Andersen, T. Ueland, E. C. Knudsen et al., “Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation,” Diabetes, vol. 60, no. 5, pp. 1544–1551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Weigert, M. Neumeier, J. Wanninger et al., “Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes,” Cytokine, vol. 45, no. 2, pp. 86–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Bodlaj, J. Berg, R. Pichler, T. Sailer, and G. Biesenbach, “Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters,” Journal of Nephrology, vol. 17, no. 1, pp. 112–117, 2004. View at Google Scholar · View at Scopus
  33. L. M. Lima, M. G. Carvalho, A. L. Soares et al., “High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 6, pp. 956–960, 2007. View at Google Scholar · View at Scopus
  34. K. Sjöholm, J. Palming, T. C. Lystig et al., “The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic disease,” Biochemical and Biophysical Research Communications, vol. 344, no. 4, pp. 1308–1314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Ebert, D. J. Phillips, P. Jenzewski, R. Nau, A. E. O'Connor, and U. Michel, “Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis,” Journal of the Neurological Sciences, vol. 250, no. 1-2, pp. 50–57, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Panunti and V. Fonseca, “Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients,” Vascular Pharmacology, vol. 45, no. 1, pp. 29–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Hirai, M. Yamanaka, H. Kawachi, T. Matsui, and H. Yano, “Activin A inhibits differentiation of 3T3-L1 preadipocyte,” Molecular and Cellular Endocrinology, vol. 232, no. 1-2, pp. 21–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. C. Alessi, D. Bastelica, P. Morange et al., “Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity,” Diabetes, vol. 49, no. 8, pp. 1374–1380, 2000. View at Google Scholar · View at Scopus
  39. S. Dennler, S. Itoh, D. Vivien, P. T. Dijke, S. Huet, and J. M. Gauthier, “Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,” The EMBO Journal, vol. 17, no. 11, pp. 3091–3100, 1998. View at Publisher · View at Google Scholar · View at Scopus